{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:51:11Z","timestamp":1791399071853,"version":"4.3.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Hepatitis B virus (HBV) infection poses increased risks for cancer patients due to immunosuppression and potential viral reactivation. We evaluated the seroprevalence and temporal trends of HBV exposure in a large cohort of cancer patients in Brazil.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients who underwent anti-HBc testing at a quaternary oncology center between 2010 and 2023 were included in this retrospective study, and HBV exposure was defined as anti-HBc positivity. Temporal trends were assessed by using linear regression, whereas associated factors were evaluated by using multivariable logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Anti-HBc testing was performed in 22.9% (28,869\/125,985) of admitted cancer patients, and seroprevalence was 13.4% (3,857\/28,869), declining from 16.5 in 2010 to 9.9% in 2023 (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001). Decreasing trends were observed across sexes and age groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001 for both), with a more pronounced decline among men (25.1%\u201312.3%). Seroprevalence also decreased significantly among White patients (16.7%\u20137.9%;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001) and those with solid tumors (18.8%\u20139.0%; p\u00a0&lt;\u00a00.001), but not among non-White individuals (21.4%\u201317.7%; p\u00a0=\u00a00.246) or those with hematological malignancies (13.1%\u201312.8%;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.136). Age \u2265 60\u00a0years (OR\u00a0=\u00a04.40; 95%CI: 3.77\u20135.12;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001), men (OR\u00a0=\u00a01.89; 95%CI: 1.76\u20132.04;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001), and non-White ethnicity\/color (OR\u00a0=\u00a01.25; 95%CI: 1.15\u20131.35;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001) were independently associated with HBV exposure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite the declining seroprevalence over time, HBV exposure remains common among cancer patients, as persistent disparities across demographic groups underscore the need for expanded vaccination and systematic screening.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10552-026-02262-w","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:37:06Z","timestamp":1791351426000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends in hepatitis B virus seroprevalence in a large cohort of adult cancer patients from 2010 to 2023"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7952-7671","authenticated-orcid":false,"given":"Marina","family":"Rossi de Camargo Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3976-6579","authenticated-orcid":false,"given":"Vict\u00f3ria Gon\u00e7alves","family":"de Paula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0621-1971","authenticated-orcid":false,"given":"D\u00e9bora Bignotto Rosane","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9640-7480","authenticated-orcid":false,"given":"Rafael","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2324-3502","authenticated-orcid":false,"given":"Gustavo Manoel","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4936-3633","authenticated-orcid":false,"given":"Caroline","family":"Manchiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3135-6582","authenticated-orcid":false,"given":"Bianca Peixoto","family":"Dantas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4908-0764","authenticated-orcid":false,"given":"F\u00e1tima Mitiko","family":"Tengan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0765-6654","authenticated-orcid":false,"given":"Edson","family":"Abdala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7416-6623","authenticated-orcid":false,"given":"Mariana Cavalheiro","family":"Magri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"2262_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2026.6070","author":"WJ Jeng","year":"2026","unstructured":"Jeng WJ, Yip TC, Lok AS (2026) Hepatitis B: a review. JAMA. https:\/\/doi.org\/10.1001\/jama.2026.6070","journal-title":"JAMA"},{"issue":"11","key":"2262_CR2","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s10552-025-02021-3","volume":"36","author":"GV Gonzalez","year":"2025","unstructured":"Gonzalez GV, Danos DM, Ferguson TF, Therapondos G, Hsieh MC, Leonardi C (2025) Clinical risk factors for hepatocellular carcinoma in Southeast Louisiana: a matched case-control study. Cancer Causes Control 36(11):1399\u20131407. https:\/\/doi.org\/10.1007\/s10552-025-02021-3","journal-title":"Cancer Causes Control"},{"key":"2262_CR3","unstructured":"World Health Organization (2026) Global hepatitis report 2026. Geneva: World Health Organization. https:\/\/www.who.int\/publications\/i\/item\/9789240122383. Accessed 29 May 2026"},{"issue":"4","key":"2262_CR4","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB (2018) Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67(4):1560\u20131599. https:\/\/doi.org\/10.1002\/hep.29800","journal-title":"Hepatology"},{"issue":"1","key":"2262_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/CLD.0000000000000195","volume":"23","author":"HC Yang","year":"2024","unstructured":"Yang HC (2024) Revisiting the natural history of chronic hepatitis B infection. Clin Liver Dis (Hoboken) 23(1):e0195. https:\/\/doi.org\/10.1097\/CLD.0000000000000195","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"2","key":"2262_CR6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jhep.2019.03.034","volume":"71","author":"G Raimondo","year":"2019","unstructured":"Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS (2019) Taormina workshop on occult HBV infection faculty members. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol 71(2):397\u2013408. https:\/\/doi.org\/10.1016\/j.jhep.2019.03.034","journal-title":"J Hepatol"},{"issue":"5\u20136","key":"2262_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1053\/j.seminoncol.2024.08.001","volume":"51","author":"N Deepan","year":"2024","unstructured":"Deepan N, Maung ST, Decharatanachart P, Chaiteerakij R (2024) Hepatitis B virus reactivation in cancer patients receiving chemotherapy-A systematic review and meta-analysis. Semin Oncol 51(5\u20136):123\u2013134. https:\/\/doi.org\/10.1053\/j.seminoncol.2024.08.001","journal-title":"Semin Oncol"},{"issue":"10","key":"2262_CR8","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.cmi.2022.02.042","volume":"28","author":"K Mustafayev","year":"2022","unstructured":"Mustafayev K, Torres H (2022) Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Clin Microbiol Infect 28(10):1321\u20131327. https:\/\/doi.org\/10.1016\/j.cmi.2022.02.042","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"2262_CR9","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","volume":"83","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver (2025) EASL 2025 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 83(2):502\u2013583. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.018","journal-title":"J Hepatol"},{"issue":"14","key":"2262_CR10","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1200\/JCO.24.00032","volume":"42","author":"M Kamboj","year":"2024","unstructured":"Kamboj M, Bohlke K, Baptiste DM, Dunleavy K, Fueger A, Jones L, Kelkar AH, Law LY, LeFebvre KB, Ljungman P, Miller ED, Meyer LA, Moore HN, Soares HP, Taplitz RA, Woldetsadik ES, Kohn EC (2024) Vaccination of adults with cancer: ASCO guideline. J Clin Oncol 42(14):1699\u20131721. https:\/\/doi.org\/10.1200\/JCO.24.00032","journal-title":"J Clin Oncol"},{"issue":"1","key":"2262_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10620-017-4850-1","volume":"63","author":"YE Kwak","year":"2018","unstructured":"Kwak YE, Stein SM, Lim JK (2018) Practice patterns in hepatitis B virus screening before cancer chemotherapy in a major US hospital network. Dig Dis Sci 63(1):61\u201371. https:\/\/doi.org\/10.1007\/s10620-017-4850-1","journal-title":"Dig Dis Sci"},{"issue":"5","key":"2262_CR12","doi-asserted-by":"publisher","first-page":"552","DOI":"10.5152\/tjg.2023.22297","volume":"34","author":"A\u015e K\u00f6ksal","year":"2023","unstructured":"K\u00f6ksal A\u015e, Toka B, Sade\u00e7olak M, Acar \u015e, Eminler AT, Tozlu M, Karabay O (2023) Electronic alert system significantly increases HBV screening rates before immunosuppressive treatments. Turk J Gastroenterol 34(5):552\u2013559. https:\/\/doi.org\/10.5152\/tjg.2023.22297","journal-title":"Turk J Gastroenterol"},{"issue":"4","key":"2262_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.12892\/ejgo4169.2018","volume":"39","author":"AHI Garces","year":"2018","unstructured":"Garces AHI, Dias MSF, Bizzo S, Paulino E, Moreira CGF, Kaye S, Thuler LCS, Melo AC (2018) Prevalence and risk factors of HBV, HCV, and HIV infections among cervical cancer patients. Eur J Gynaecol Oncol 39(4):585\u2013589. https:\/\/doi.org\/10.12892\/ejgo4169.2018","journal-title":"Eur J Gynaecol Oncol"},{"issue":"4","key":"2262_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/jamaoncol.2018.6437","volume":"5","author":"SD Ramsey","year":"2019","unstructured":"Ramsey SD, Unger JM, Baker LH, Little RF, Loomba R, Hwang JP, Chugh R, Konerman MA, Arnold K, Menter AR, Thomas E, Michels RM, Jorgensen CW, Burton GV, Bhadkamkar NA, Hershman DL (2019) Prevalence of hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly diagnosed cancer from academic and community oncology practices. JAMA Oncol 5(4):497\u2013505. https:\/\/doi.org\/10.1001\/jamaoncol.2018.6437","journal-title":"JAMA Oncol"},{"issue":"6","key":"2262_CR15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3329\/jhpn.v29i6.9903","volume":"29","author":"S Kose","year":"2011","unstructured":"Kose S, Olmezoglu A, Gozaydin A, Ece G (2011) Seroprevalence of hepatitis B and C among oncology patients in Turkey. J Health Popul Nutr 29(6):652\u2013655. https:\/\/doi.org\/10.3329\/jhpn.v29i6.9903","journal-title":"J Health Popul Nutr"},{"issue":"3","key":"2262_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s00705-026-06562-z","volume":"171","author":"MC Magri","year":"2018","unstructured":"Magri MC, Manchiero C, Dantas BP, Bernardo WM, Abdala E, Tengan FM (2018) Prevalence of hepatitis B in Latin America and the Caribbean: a systematic review and meta-analysis. Arch Virol 171(3):88. https:\/\/doi.org\/10.1007\/s00705-026-06562-z","journal-title":"Arch Virol"},{"key":"2262_CR17","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade e Ambiente (2025) Boletim Epidemiol\u00f3gico - Hepatites virais 2025. Bras\u00edlia (DF): Minist\u00e9rio da Sa\u00fade. https:\/\/www.gov.br\/saude\/pt-br\/centrais-de-conteudo\/publicacoes\/boletins\/epidemiologicos\/especiais\/2025\/boletim-epidemiologico-de-hepatites-virais.pdf. Accessed 27 May 2026"},{"key":"2262_CR18","doi-asserted-by":"publisher","DOI":"10.1590\/1980-549720240033","volume":"27","author":"CA Mariz","year":"2024","unstructured":"Mariz CA, Braga C, Albuquerque MFPM, Luna CF, Salustiano DM, Freire NM, Morais CNL, Lopes EP (2024) Occurrence of hepatitis B and C virus infection in socioeconomic population strata from Recife, Pernambuco, Northeast Brazil. Rev Bras Epidemiol 27:e240033. https:\/\/doi.org\/10.1590\/1980-549720240033","journal-title":"Rev Bras Epidemiol"},{"key":"2262_CR19","doi-asserted-by":"publisher","DOI":"10.1590\/1980-220X-REEUSP-2025-0358en","volume":"60","author":"TS Amaral","year":"2026","unstructured":"Amaral TS, Souza SO, Matos MAD, Meireles GOAB, Paula CR, Matos MA (2026) Seroprevalence of markers and immunization for hepatitis B in community health workers: a scoping review. Rev Esc Enferm USP 60:e20250358. https:\/\/doi.org\/10.1590\/1980-220X-REEUSP-2025-0358en","journal-title":"Rev Esc Enferm USP"},{"key":"2262_CR20","first-page":"1","volume":"361","author":"D Kruszon-Moran","year":"2020","unstructured":"Kruszon-Moran D, Paulose-Ram R, Martin CB, Barker LK, McQuillan G (2020) Prevalence and trends in hepatitis B virus infection in the United States, 2015\u20132018. NCHS Data Brief 361:1\u20138","journal-title":"NCHS Data Brief"},{"issue":"1","key":"2262_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40249-022-01032-5","volume":"11","author":"Z Liu","year":"2022","unstructured":"Liu Z, Li M, Hutton DW, Wagner AL, Yao Y, Zhu W, Cao L, Tang S, Pan J, Wang Y, Zhao Q, Ren H, Wang Y, Wang W (2022) Impact of the national hepatitis B immunization program in China: a modeling study. Infect Dis Poverty 11(1):106. https:\/\/doi.org\/10.1186\/s40249-022-01032-5","journal-title":"Infect Dis Poverty"},{"key":"2262_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2025.102946","volume":"99","author":"MC Magri","year":"2025","unstructured":"Magri MC, de Paula VG, Pinto MRC, Battaglia DBR, de Oliveira R, Ferreira GM, Tengan FM, Abdala E (2025) Prevalence of vaccine-induced immunity to hepatitis B in cancer patients: A 13-year analysis in a quaternary oncological center. Cancer Epidemiol 99:102946. https:\/\/doi.org\/10.1016\/j.canep.2025.102946","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"2262_CR23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12889-023-15130-y","volume":"23","author":"X Xu","year":"2023","unstructured":"Xu X, Wu C, Lou Z, Peng C, Jiang L, Wu T, Zeng T, Dong Y, Ruan B (2023) Changing incidence of hepatitis B and persistent infection risk in adults: a population-based follow-up study from 2011 in China. BMC Public Health 23(1):256. https:\/\/doi.org\/10.1186\/s12889-023-15130-y","journal-title":"BMC Public Health"},{"issue":"9","key":"2262_CR24","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.31557\/APJCP.2021.22.9.2939","volume":"22","author":"S Mahmoudvand","year":"2021","unstructured":"Mahmoudvand S, Shokri S, Mirzaei H, Ramazani A, Makvandi M, Neisi N, Hashemi SJ (2021) Frequency of hepatitis B virus infection among patients before chemotherapy treatment. Asian Pac J Cancer Prev 22(9):2939\u20132944. https:\/\/doi.org\/10.31557\/APJCP.2021.22.9.2939","journal-title":"Asian Pac J Cancer Prev"},{"key":"2262_CR25","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.17601.3","author":"R Brown","year":"2022","unstructured":"Brown R, Goulder P, Matthews PC (2022) Sexual dimorphism in chronic hepatitis B virus (HBV) infection: evidence to inform elimination efforts. Well Open Res. https:\/\/doi.org\/10.12688\/wellcomeopenres.17601.3","journal-title":"Well Open Res"},{"issue":"8","key":"2262_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236993","volume":"15","author":"C Cabezas","year":"2020","unstructured":"Cabezas C, Trujillo O, Balbuena J, Peceros FM, Terrazas M, Su\u00e1rez M, Marin L, Apac J, Ram\u00edrez-Soto MC (2020) Decrease in the prevalence of hepatitis B and D virus infections in an endemic area in Peru 23 years after the introduction of the first pilot vaccination program against hepatitis B. PLoS ONE 15(8):e0236993. https:\/\/doi.org\/10.1371\/journal.pone.0236993","journal-title":"PLoS ONE"},{"issue":"12","key":"2262_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13121082","volume":"13","author":"J Heisig","year":"2024","unstructured":"Heisig J, Nurmatov ZS, Riese P, Trittel S, Sattarova GJ, Temirbekova SN, Zhumagulova GZ, Nuridinova ZN, Derkenbaeva AA, Arykbaeva BK, Dzhangaziev BI, Prokein J, Klopp N, Illig T, Guzm\u00e1n CA, Kasymov OT, Akmatov MK, Pessler F (2024) Vaccination schedule and age influence impaired responsiveness to hepatitis B vaccination: a randomized trial in Central Asia. Pathogens (Basel) 13(12):1082. https:\/\/doi.org\/10.3390\/pathogens13121082","journal-title":"Pathogens (Basel)"},{"issue":"1","key":"2262_CR28","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jcv.2013.07.003","volume":"58","author":"AP Vermeiren","year":"2013","unstructured":"Vermeiren AP, Hoebe CJ, Dukers-Muijrers NH (2013) High non-responsiveness of males and the elderly to standard hepatitis B vaccination among a large cohort of healthy employees. J Clin Virol 58(1):262\u2013264. https:\/\/doi.org\/10.1016\/j.jcv.2013.07.003","journal-title":"J Clin Virol"},{"issue":"6","key":"2262_CR29","doi-asserted-by":"publisher","first-page":"815","DOI":"10.5604\/16652681.1171756","volume":"14","author":"FP Pinto","year":"2015","unstructured":"Pinto FP, Ferreira JOC, Olmedo DB, Precioso PM, Barquette FRS, Castilho MC, Silva SGC, P\u00f4rto LC (2015) Prevalence of hepatitis B and C markers in a population of an urban university in Rio de Janeiro, Brazil: a cross-sectional study. Ann Hepatol 14(6):815\u2013825. https:\/\/doi.org\/10.5604\/16652681.1171756","journal-title":"Ann Hepatol"},{"issue":"2","key":"2262_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264062","volume":"17","author":"J LaMori","year":"2022","unstructured":"LaMori J, Feng X, Pericone CD, Mesa-Frias M, Sogbetun O, Kulczycki A (2022) Hepatitis vaccination adherence and completion rates and factors associated with low compliance: a claims-based analysis of U.S. adults. PLoS ONE 17(2):e0264062. https:\/\/doi.org\/10.1371\/journal.pone.0264062","journal-title":"PLoS ONE"},{"issue":"6","key":"2262_CR31","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.21873\/invivo.13346","volume":"37","author":"M Papadakis","year":"2023","unstructured":"Papadakis M, Karniadakis I, Mazonakis N, Akinosoglou K, Tsioutis C, Spernovasilis N (2023) Immune checkpoint inhibitors and infection: what is the interplay? In Vivo 37(6):2409\u20132420. https:\/\/doi.org\/10.21873\/invivo.13346","journal-title":"In Vivo"},{"issue":"9","key":"2262_CR32","doi-asserted-by":"publisher","first-page":"617","DOI":"10.6004\/jnccn.2024.0056","volume":"22","author":"LR Baden","year":"2024","unstructured":"Baden LR, Swaminathan S, Almyroudis NG, Angarone M, Baluch A, Barros N, Buss B, Cohen S, Cooper B, Chiang AD, Boghdadly ZE, Gregg K, Hakim H, Ho D, Khawaja F, Lee R, Lee F, Logan C, Manley K, Multani A, Pande A, Pergam S, Pisano J, Saullo J, Schuster M, Seo SK, Shoham S, Taplitz R, Topal J, Wilson JW, Zimmer A, Cassara CJ, Kumar R, Diwan Z (2024) Prevention and treatment of cancer-related infections, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 22(9):617\u2013644. https:\/\/doi.org\/10.6004\/jnccn.2024.0056","journal-title":"J Natl Compr Canc Netw"},{"key":"2262_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4103\/abr.abr_330_13","volume":"6","author":"M Meidani","year":"2017","unstructured":"Meidani M, Khorvash F, Hemati S, Ashrafi F, Ataei B, Daneshmand D (2017) The immune response of vaccination against hepatitis B virus in Iranian patients undergoing chemotherapy. Adv Biomed Res 6:88. https:\/\/doi.org\/10.4103\/abr.abr_330_13","journal-title":"Adv Biomed Res"},{"issue":"3","key":"2262_CR34","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/0300060516638992","volume":"44","author":"B Yilmaz","year":"2016","unstructured":"Yilmaz B, Erdem D, Teker F, Goren I, Yildirim B, Kut E, Sarikaya D, Atay MH, Yucel I (2016) The effect of anticancer therapy on anti-hepatitis B antibody titres in patients with haematological malignancies and solid tumours. J Int Med Res 44(3):627\u2013638. https:\/\/doi.org\/10.1177\/0300060516638992","journal-title":"J Int Med Res"},{"issue":"1","key":"2262_CR35","doi-asserted-by":"publisher","DOI":"10.1097\/CLD.0000000000000143","volume":"23","author":"C Mezzacappa","year":"2024","unstructured":"Mezzacappa C, Lim JK (2024) Management of HBV reactivation: challenges and opportunities. Clin Liver Dis (Hoboken) 23(1):e0143. https:\/\/doi.org\/10.1097\/CLD.0000000000000143","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"5","key":"2262_CR36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/ejh.13388","volume":"104","author":"X Zhou","year":"2020","unstructured":"Zhou X, Wuchter P, Egerer G, Kriegsmann M, Kommoss FKF, Witzens-Harig M, Kriegsmann K (2020) Serological hepatitis B virus (HBV) activity in patients with HBV infection and B-cell non-Hodgkin\u2019s lymphoma. Eur J Haematol 104(5):469\u2013475. https:\/\/doi.org\/10.1111\/ejh.13388","journal-title":"Eur J Haematol"},{"issue":"8","key":"2262_CR37","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/jvh.12892","volume":"25","author":"M Li","year":"2018","unstructured":"Li M, Gan Y, Fan C, Yuan H, Zhang X, Shen Y, Wang Q, Meng Z, Xu D, Tu H (2018) Hepatitis B virus and risk of non-Hodgkin lymphoma: an updated meta-analysis of 58 studies. J Viral Hepat 25(8):894\u2013903. https:\/\/doi.org\/10.1111\/jvh.12892","journal-title":"J Viral Hepat"},{"key":"2262_CR38","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/ijc.70186","volume":"158","author":"L Qiu","year":"2026","unstructured":"Qiu L, Bai S, Cai J, Fang Y, Wang J, Fang X, Xia Y, Huang H, Bai B, Nie M, Zhang Y, Cai Q (2026) Antiviral prophylaxis for hepatitis B virus reactivation in T-cell lymphoma patients with resolved hepatitis B virus infection. Int J Cancer 158:1599\u20131607. https:\/\/doi.org\/10.1002\/ijc.70186","journal-title":"Int J Cancer"},{"issue":"5","key":"2262_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/v14050986","volume":"14","author":"GEM Rizzo","year":"2022","unstructured":"Rizzo GEM, Cabibbo G, Crax\u00ec A (2022) Hepatitis B virus-associated hepatocellular carcinoma. Viruses 14(5):986. https:\/\/doi.org\/10.3390\/v14050986","journal-title":"Viruses"},{"issue":"1","key":"2262_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13027-022-00457-9","volume":"17","author":"Y Wang","year":"2022","unstructured":"Wang Y, Yuan Y, Gu D (2022) Hepatitis B and C virus infections and the risk of biliary tract cancers: a meta-analysis of observational studies. Infect Agent Cancer 17(1):45. https:\/\/doi.org\/10.1186\/s13027-022-00457-9","journal-title":"Infect Agent Cancer"},{"issue":"6","key":"2262_CR41","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/ijc.33891","volume":"150","author":"T Liu","year":"2022","unstructured":"Liu T, Song C, Zhang Y, Siyin ST, Zhang Q, Song M, Cao L, Shi H (2022) Hepatitis B virus infection and the risk of gastrointestinal cancers among Chinese population: a prospective cohort study. Int J Cancer 150(6):1018\u20131028. https:\/\/doi.org\/10.1002\/ijc.33891","journal-title":"Int J Cancer"},{"issue":"3","key":"2262_CR42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/ajco.14055","volume":"20","author":"ST Maung","year":"2024","unstructured":"Maung ST, Deepan N, Decharatanachart P, Chaiteerakij R (2024) Screening for viral hepatitis B infection in cancer patients before receiving chemotherapy - a systematic review and meta-analysis. Asia Pac J Clin Oncol 20(3):335\u2013345","journal-title":"Asia Pac J Clin Oncol"}],"container-title":["Cancer Causes &amp; Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-026-02262-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10552-026-02262-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-026-02262-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:02:37Z","timestamp":1791396157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10552-026-02262-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2262"],"URL":"https:\/\/doi.org\/10.1007\/s10552-026-02262-w","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"1 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee for Analysis of Research Projects of the Clinical Hospital, Faculty of Medicine, University of Sao Paulo (\n                      Hospital das Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo\n                      \u2014HCFMUSP) (protocol numbers: 6.120.828 and 6.718.762). Informed consent was waived owing to the retrospective nature and large sample size of the study.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"178"}}